DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors
03 Octobre 2022 - 10:30PM
DBV Technologies Announces Appointment of New Chair of its Audit
Committee and Appointment of Daniele Guyot-Caparros to Board of
Directors
Montrouge, France, October 3, 2022
DBV Technologies
Announces Appointment of
New Chair of its Audit Committee and
Appointment of Daniele
Guyot-Caparros to Board of Directors
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced that Mr. Timothy E.
Morris, Independent Director and Member of the Audit Committee of
the Board of Directors (“the Board”), was appointed as Chairperson
of the Board’s Audit Committee in replacement of Ms. Viviane
Monges, who resigned from the Board effective October 3, 2022. DBV
also announced the Board’s provisional appointment of Ms. Daniele
Guyot-Caparros as Independent Director to fill Ms. Monges’ vacancy,
effective October 3, 2022. With these changes, the Board comprises
10 members.
Mr. Morris has been a member of DBV
Technologies’ Board and Audit Committee since April 2021. Mr.
Morris has served as the Chief Operating Officer and Chief
Financial Officer of Humanigen, Inc. since August 2020. He
currently serves on the board of Aquestive Therapeutics (Nasdaq:
AQST), Univercells S.A. and Humanetics (private). Mr. Morris has 38
years of professional finance and accounting experience, including
25 years as Chief Financial Officer of public biotechnology
companies.
Ms. Monges served as a Member of the Company’s
Board and Audit Committee since May 2019 and Chairperson of the
Board’s Audit Committee since March 2021.
“We are delighted to welcome Tim Morris to this
new role as Chairperson of the Board’s Audit Committee,” said
Michel de Rosen, Chairman of the Board. “Tim’s financial acumen has
been very useful to DBV Technologies since his joining the Board,
and I am confident that his demonstrated expertise and experience
will serve him well in this new capacity. On behalf of the Board,
DBV’s management team and shareholders, I thank Viviane for her
service and commitment to the Company. We greatly appreciate the
leadership and insight Viviane has provided to our Board and its
Audit Committee and wish her well in her next endeavors.”
“I have enjoyed my time as a Member of the Board
of DBV Technologies and Chairperson of its Audit Committee. I
believe in the Viaskin technology that DBV is working hard to
develop and have confidence that it may one day bring significant
benefit to patients if approved. I wish the best to the Company and
to my colleagues of the Board,” said Ms. Monges.
The Board of DBV Technologies has finalized the
provisional appointment of a new Independent Director to fill the
vacancy left by Ms. Monges and to join the Audit Committee of the
Board. Ms. Daniele Guyot-Caparros joins as a new Independent
Director to the Board, subject to ratification by the Company’s
shareholders at the next annual meeting of shareholders, and as a
Member of the Board’s Audit Committee. Ms. Guyot-Caparros has a
longstanding track record in finance and business operations. She
began her career in audit and corporate finance with
PricewaterhouseCoopers (PwC) and later joined Rhône-Poulenc-Rorer
(later Aventis and Sanofi) where she held several senior finance
positions including Chief Financial Officer, Global Research and
Development and Chief Financial Officer, Europe, Group Planning.
Ms. Guyot-Caparros also held responsibilities in business
development, pricing and portfolio management. In 2008, Ms.
Guyot-Caparros became Senior Advisor for Deloitte France to support
the development of the Life Sciences and Health Care Industry
practice.
“I am thrilled to join DBV Technologies’ Board
of Directors at a significant time in the Company’s regulatory
journey,” said Ms. Guyot-Caparros. “I am encouraged by the release
of DBV’s EPITOPE results in 1- to 3-year-old peanut allergic
children and look forward to supporting the Company’s continued
progress with regards to the VITESSE Phase 3 pivotal study in 4- to
7-year-old peanut allergic children. These are critical age groups
in this disease area, and families are long overdue for additional
treatment options. I am eager to contribute to the responsible
oversight of DBV’s financial management to adequately support these
and other clinical priorities.”
In addition to in-house experience, Ms.
Guyot-Caparros has held positions on the boards of biotechnology
and medical technology companies. She was both a Board Member and
Audit Committee Member at Diaxonhit (now Eurobio Scientific),
listed on Euronext Growth. Ms. Guyot-Caparros was also Chairperson
of the Audit Committee of Supersonic Imagine from July 2018 to
September 2019 until its acquisition. From 2013 to 2022, she has
been the Chairperson of the Audit Committee of Onxeo, and also
served as the Chairperson of its Board of Directors from May 2019
to July 2021.
“We welcome Daniele Guyot-Caparros as a new
director to the DBV Board,” said Michel de Rosen, Chairman of the
Board. “Daniele has rich experience in senior financial positions
with diverse companies across the chemical, pharmaceutical and
medical technology industries. She has served in prior board and
audit committee positions where she has proven her strong
leadership that will complement DBV’s Board of Directors. Daniele’s
appointment is part of our Board evolution as we continue to focus
on having the right mix of skills and experience to achieve our
strategic and financial objectives.”
The provisional appointment of Ms.
Guyot-Caparros will be submitted to a shareholder vote at the 2023
Ordinary and Extraordinary General Meeting. Details and procedures
with respect to DBV Technologies’ 2023 Ordinary and Extraordinary
General Meeting will be communicated by the Company at a later
date.
About DBV TechnologiesDBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, and is DBV Technologies’ method of delivering biologically
active compounds to the immune system through intact skin. With
this new class of non-invasive product candidates, the Company is
dedicated to safely transforming the care of food allergic
patients. DBV Technologies’ food allergies programs include ongoing
clinical trials of Viaskin Peanut. DBV Technologies has global
headquarters in Montrouge, France, and North American operations in
Basking Ridge, NJ. The Company’s ordinary shares are traded on
segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345)
and the Company’s ADSs (each representing one-half of one ordinary
share) are traded on the Nasdaq Global Select Market (Ticker:
DBVT).
Forward-Looking StatementsThis
press release may contain forward-looking statements and estimates,
including statements regarding DBV Technologies’ regulatory process
and the potential of DBV Technologies’ pipeline. These
forward-looking statements and estimates are not promises or
guarantees and involve substantial risks and uncertainties and may
be impacted by market conditions as well as other risks and
uncertainties set forth in DBV Technologies’ regulatory filings
with the Autorité des Marchés Financiers (“AMF”), DBV Technologies’
filings and reports with the U.S. Securities and Exchange
Commission (“SEC”), and future filings and reports made with the
AMF and SEC. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements and
estimates, which speak only as of the date hereof. Other than as
required by applicable law, DBV Technologies undertakes no
obligation to update or revise the information contained in this
Press Release.
Investor Contact Anne PollakDBV
Technologies+1 857-529-2363anne.pollak@dbv-technologies.com
Media Contact Angela
MarcucciDBV
Technologies+1 646-842-2393angela.marcucci@dbv-technologies.com
Viaskin and EPIT are trademarks of DBV
Technologies.
DBV Technologies (EU:DBV)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
DBV Technologies (EU:DBV)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024